Search Results for: DNA VACCINE TECHNOLOGY A Vaccine
Articles
Akston Biosciences & LakePharma Announce Strategic Partnership to Manufacture Second-Generation COVID-19 Vaccine January 5, 2021
Akston Biosciences and LakePharma recently announced they have established a strategic partnership in which LakePharma will manufacture commercial quantities of Akston’s...Recipharm Signs Agreement With Arcturus Therapeutics to Support the Manufacture of LUNAR-COV19 (ARCT-021) Vaccine Candidate October 7, 2020
Recipharm has recently entered into an agreement with Arcturus Therapeutics, a leading US-based clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and….
PLATFORM TECHNOLOGY - Morphomer(TM) & SupraAntigen(TM) Platforms: Targeting Misfolded Proteins in Neurodegenerative Disorders October 1, 2020
Andrea Pfeifer, PhD, details the efforts to develop the therapeutic and diagnostic tools necessary to enable precision medicine approaches targeting the right protein, at the right time, in the right patient.
Arcturus Therapeutics Announces Dosing of its COVID-19 Vaccine Candidate in Phase 1/2 Study August 12, 2020
Arcturus Therapeutics Holdings Inc. recently announced that all subjects in the first cohort have been dosed in the Phase 1/2...Arcturus Therapeutics & Catalent Announce Partnership to Manufacture mRNA-Based COVID-19 Vaccine May 5, 2020
Arcturus Therapeutics Holdings Inc. and Catalent, Inc.recently announced a partnership to support the expected manufacture of Arcturus’ COVID-19 mRNA vaccine candidate (LUNAR-COV19), intended to….
OncoSec Collaborates With Providence Cancer Institute to Conduct First-in-Human Trial of Investigational Vaccine to Prevent COVID-19 April 9, 2020
OncoSec Medical Incorporated recently announced that Providence Cancer Institute, a part of Providence St. Joseph Health, is pursuing a first-in-human Phase 1 clinical trial of OncoSec’s novel….
Arcturus Therapeutics & Duke-NUS Medical School Partner to Develop a COVID-19 Vaccine March 5, 2020
Arcturus Therapeutics and Duke-NUS Medical School (Duke-NUS) recently announced their partnership to develop a Coronavirus….
Inovio Develops Novel H3N2 Influenza DNA Vaccine; Generates Cross-Reactive Responses & Provides Complete Protection Against Lethal Preclinical Challenges September 20, 2018
Inovio Pharmaceuticals, Inc. recently announced its SynCon vaccine approach using a collection of DNA antigens generated broadly protective antibody responses...Vaccinex & Catalent Biologics to Collaborate on Antibody-Drug Conjugate Development November 30, 2017
Catalent Pharma Solutions and Vaccinex, Inc. recently announced an agreement to develop an antibody-drug conjugate (ADC) using Catalent’s proprietary SMARTag®...AELIX Therapeutics Enrolls First Patient in HIV Vaccine Trial September 11, 2017
AELIX Therapeutics recently announced that it has enrolled the first patient in its Phase 1 clinical trial for the assessment...Inovio’s DNA-Based Monoclonal Antibody Platform Achieves Further Proof-of-Principle Validation July 7, 2017
Inovio Pharmaceuticals, Inc. recently announced its DNA-based monoclonal antibody product for flu produced broadly cross-reactive antibodies that provided complete protection...Inovio HIV Vaccine Elicits Nearly 100% Immune Response Rates in a Clinical Study May 30, 2017
Inovio Pharmaceuticals, Inc. recently announced that its HIV vaccine, PENNVAX-GP, produced amongst the highest overall levels of immune response rates...PROTEIN THERAPEUTICS MARKET - Technology Advances Spur Market Growth of Protein Therapies November 7, 2016
Laurie L. Sullivan and Shalini S. Dewan, BCC Research Analysts, believe with the advent of genetic engineering and recombinant DNA technology, it is now possible to produce a wide variety of human proteins, and that these novel technologies have lifted the market for therapeutic proteins to new heights.
Cobra Biologics & Touchlight Collaborate on Production of Next-Generation DNA Constructs June 14, 2016
Cobra Biologics Ltd and Touchlight are collaborating on a project to optimize the manufacture of Adeno-Associated Virus (AAV) vectors used...Technology Advancements in Protein Therapeutics Spurring Market Growth to $248.7 Billion May 31, 2016
Protein drugs have gained importance for their therapeutic applications, and the numbers of products have increased in recent years. BCC...Inovio Pharmaceuticals Acquires Needle-Free Injection Technology to Advance Strategy for Next-Generation Vaccines March 18, 2016
Inovio Pharmaceuticals, Inc. recently announced it has signed a definitive agreement to acquire all of Bioject Medical Technologies Inc.’s assets,...Inovio Pharmaceutical's DNA Vaccine for Zika Virus Induces Robust Immune Responses February 22, 2016
Inovio Pharmaceuticals, Inc. recently announced that preclinical testing of its synthetic vaccine for the Zika virus induced robust and durable...BIOTHERAPEUTICS DEVELOPMENT - The Role of Flow Electroporation in Vaccine Development May 4, 2015
James Brady, PhD, Karen Donato, PhD, and Krista Steger, PhD, indicate that with unmatched quality, flexibility, and scalability, flow electroporation is a universal, cost-effective platform that supports the full range of biotherapeutic and vaccine development activities.
DNA VACCINES MARKET - DNA Vaccines: Strategic Markets & Emerging Technologies November 17, 2014
Kevin James, Shalini Dewan, MS, and Jon Evans, MBA, say the global market for DNA vaccines is estimated at $305.3 million for 2014 and is forecast to grow at a stellar 54.8% compound annual growth rate (CAGR) to reach $2.7 billion by 2019.
VACCINE TECHNOLOGY - Vaccine Technologies & the Rationale for New Nanoparticle Formulations October 3, 2014
Robert S. Becker, PhD, MBA, and Mark A. Mitchnick, MD, explain how SATx technology provides a new flexible formulation platform for the generation of nanoparticulate vaccine formulations without the limitations of previous formulation technologies that have inhibited the optimization of vaccine potencies and safety profiles.